Regeneron

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Regeneron 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About REGN

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. 

CEO
Leonard S. Schleifer
CEOLeonard S. Schleifer
Employees
15,106
Employees15,106
Headquarters
Tarrytown, New York
HeadquartersTarrytown, New York
Founded
1988
Founded1988
Employees
15,106
Employees15,106

REGN Key Statistics

Market cap
82.83B
Market cap82.83B
Price-Earnings ratio
19.07
Price-Earnings ratio19.07
Dividend yield
0.44%
Dividend yield0.44%
Average volume
686.61K
Average volume686.61K
High today
$817.11
High today$817.11
Low today
$785.83
Low today$785.83
Open price
$810.00
Open price$810.00
Volume
198.76K
Volume198.76K
52 Week high
$821.11
52 Week high$821.11
52 Week low
$476.49
52 Week low$476.49

Stock Snapshot

Regeneron(REGN) stock is priced at $788.12, giving the company a market capitalization of 82.83B. It carries a P/E multiple of 19.07 and pays a dividend yield of 44.2%.

On 2026-01-12, Regeneron(REGN) stock moved within a range of $785.83 to $817.11. With shares now at $788.12, the stock is trading +0.3% above its intraday low and -3.5% below the session's peak.

Trading activity shows a volume of 198.76K, compared to an average daily volume of 686.61K.

The stock's 52-week range extends from a low of $476.49 to a high of $821.11.

The stock's 52-week range extends from a low of $476.49 to a high of $821.11.

REGN News

Simply Wall St 3h
Assessing Regeneron Pharmaceuticals Valuation After Recent Analyst Buy Upgrades

Advertisement Analyst upgrades and what they might mean for REGN Regeneron Pharmaceuticals (REGN) has come into focus after multiple analysts, including Bank...

Assessing Regeneron Pharmaceuticals Valuation After Recent Analyst Buy Upgrades
Simply Wall St 3d
Is Regeneron Offering Value After Recent Share Price Strength And DCF Assessment

If you are wondering whether Regeneron Pharmaceuticals' current share price lines up with its underlying worth, you are not alone. This article is built to help...

Is Regeneron Offering Value After Recent Share Price Strength And DCF Assessment
Nasdaq 4d
REGN Crosses Above Average Analyst Target

In recent trading, shares of Regeneron Pharmaceuticals, Inc. (Symbol: REGN) have crossed above the average analyst 12-month target price of $816.30, changing ha...

REGN Crosses Above Average Analyst Target

Analyst ratings

70%

of 30 ratings
Buy
70%
Hold
30%
Sell
0%

More REGN News

Benzinga 5d
Regeneron Just Moved From Underperform To Buy - Here's Why

Could the tide be turning for Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) after a surprising shift in analyst sentiment? As investors digest the latest upgrad...

Regeneron Just Moved From Underperform To Buy - Here's Why
TipRanks 5d
Regeneron upgraded to Buy from Underperform at BofA

BofA upgraded Regeneron (REGN) to Buy from Underperform with a price target of $860, up from $627. Claim 70% Off TipRanks Premium Published first on TheFly –...

TipRanks 7d
Sanofi and Regeneron Expand Dupilumab’s Real-World Footprint in Chronic Urticaria

Regeneron Pharmaceuticals (REGN), Sanofi SA (SNY) announced an update on their ongoing clinical study. Claim 70% Off TipRanks This Holiday Season Study Overvi...

People also own

Based on the portfolios of people who own REGN. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.